Vitiligo
☆ AI Dermatology — Free Service
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
Vitiligo di e mani hè più difficiule da trattà chè in l’altri parti di u corpu. Oltre à esse cosmeticamente sgradevule, u vitiligo hè una condizione normale è ùn hè micca contagiosa. In dermatologia, u trattamentu più efficace hè a fototerapia o u trattamentu laser (excimer) 2‑3 volte à settimana per almenu un annu. Se ùn pudete micca andà spessu à l’ospedale per ragioni finanziarie o perchè site occupatu, pudete pruvà una macchina di fototerapia chì hè appruvata per l’usu in casa.
Vitiligo palpebrale.
Vitiligo in manu
relevance score : -100.0%
ReferencesVitiligo hè un disordine cumunu di a pelle chì provoca macchie di pelle bianca per a perdita di melanociti. Ricerche recenti mostranu chì hè una malatia autoimmune. Ancu s'ellu hè spessu vistu cum'è un prublema cusmeticu, pò influenzà profondamente u benessere mentale è a vita cutidiana. In u 2011, l'esperti anu classificatu un tipu chjamatu segmental vitiligo separatamente da l'altri.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
I pazienti cun vitiligo attivu anu parechje opzioni terapeutiche, cum'è i glucocorticoidi sistemici, a fototerapia è l’immunosoppressori sistemichi. I malati di vitiligo stabile ponu truvà sollievu da corticosteroidi topichi, inibitori di calcineurina topichi, fototerapia è prucessi di trasplante. Avanzamenti recenti in a capiscitura di i prucessi sottostanti di vitiligo anu purtatu à u sviluppu di terapie mirate. Attualmente, l’inibitori di JAK sò i più promettenti, chì offrenu una bona tolerabilità è risultati funzionali, malgradu u risicu d’attivà infezzioni latenti è effetti laterali sistemichi cumuni cù altri agenti immunosuppressivi. A ricerca in corsu hà per scopu di identificà e citochine chjave implicate in u sviluppu di vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). U bloccu di ste citochine hà dimustratu prumessa in mudelli animali è in certi pazienti. Inoltre, investigazioni nantu à terapie basate annantu à miRNA è terapia adoptiva di cellule Treg sò in corsu.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ùn ci hè micca cura cunnisciuta per u vitiligo. Per quelli chì anu a pelle clara, a crema solare è u trucco sò ciò chì tipicamente si cunsiglia. Altre opzioni di trattamentu ponu include creme steroidi o fototerapia.
○ Trattamentu
#Phototherapy
#Excimer laser
#Tacrolimus ointment